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A B S T R A C T
Mammography is the predominant screening method for early detection of breast cancer,
but has limitations and could be rendered more accurate by combination with a blood-
based biomarker profile. Circulating microRNAs (miRNAs) are increasingly recognized as
strong biomarkers, and we previously developed a 9-miRNA profile using serum and
LNA-based qPCR that effectively stratified patients with early stage breast cancer vs.
healthy women. To further develop the test into routine clinical practice, we collected
serum of women examined by clinical mammography (N ¼ 197) according to standard
operational procedures (SOPs) of the Danish Cancer Biobank. The performance of the circu-
lating 9-miRNA profile was analyzed in 116 of these women, including 36 with breast can-
cer (aged 50e74), following a standardized protocol that mimicked a routine clinical set-up.
We confirmed that the profile is significantly different between women with breast cancer
and controls (p-value <0.0001), with an AUC of 0.61. Significantly, one woman whose 9-
miRNA profile predicted a 73% probability of having breast cancer indeed developed the
disease within one year despite being categorized as clinically healthy at the time of blood
sample collection and mammography. We propose that this miRNA profile combined with
mammography will increase the overall accuracy of early detection of breast cancer.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor 2; miRNA, microRNA; SOP, standard operational proced-
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1. Introduction
Mammography is currently the standard screening method
for breast cancer inmany countries, fulfilling theWHO criteria
(Chestnov et al., 2014). However, the method has limitations
due to relatively high false-positive rates, and limitations in
detecting smaller tumors, including those in dense breast tis-
sue (Nelson et al., 2016a,b). In 2014, WHO published an
updated position on mammography screening (Chestnov
et al., 2014) to provide independent guidance on the balance
between benefits and harm in women of different age groups.
In well-resourced settings, such as many Western Countries,
biennial screening is suggested for women aged 50e69 years
(Mittmann et al., 2015), which is the current screening inter-
val, and age-range, in Denmark.
Mammograms are increasingly becoming digitalized
(computerized) and being developed further as a new tomo-
graphic technique, termed digital breast tomosynthesis
(DBT) (Gilbert et al., 2016). Despite these technological devel-
opments, however, there are still limitations resulting in
false-positive and -negative results, and implementation of
these advanced digitalized techniques is costly and conse-
quently difficult in many countries. Nuclear breast imaging
in which radiotracers are used for functional screening rather
than X-ray-based anatomic screening (Berg, 2016) has been
tested in women with a high-risk of developing breast cancer,
and has potential for population-based screening, although
likely not in the near future.
Thus, there is great interest in identifying circulating bio-
markers to screen for early stage cancer using blood of
seemingly healthy individuals. These circulating biomarkers
include nucleic acid fragments shed into the blood stream
from cancerous cells, either apoptotic or necrotic, or as an
active secretory process (Schwarzenbach et al., 2014). The
notion of a “liquid biopsy” has several advantages since
circulating nucleotides (miRNA/DNA) are highly stable in
the blood-stream (Kosaka et al., 2010; Mitchell et al., 2008),
likely represent the entire tumor vs. an isolated tumor nee-
dle biopsy, permit automation of most of the analysis, and
support compliance due to minimal discomfort. The pres-
ence of miRNA in the blood of cancer patients is believed
to have a half-life ranging from 15 min to several hours,
similar to cell-free DNA (Schwarzenbach et al., 2014;
Minchin et al., 2001; Botezatu et al., 2000), providing contin-
uous markers of the cancer applicable to screening as well
as monitoring potential recurrence, and perhaps also
serving as early markers of the effect of certain cancer
treatments.
The first report of miRNAs in the blood stream in 2008
(Chim et al., 2008; Lawrie et al., 2008) initiated an intense
search for these markers for various diseases, but enthusiasm
for using miRNAs has been challenged in recent years
(Witwer, 2015; Schwarzenbach et al., 2014). Issues raised
include the risk that miRNAs may represent the body’s
“danger” response to a cancer more than the tumor itself.
There are also limitations with reproducibility of miRNA pro-
files attributed to variability of pre-analytical handling, popu-
lation diversity and varying technologies used. Despite these
concerns, development in this field continues, since blood-
based biomarker assays have great clinical potential and miR-
NAs are excellent candidates.
We previously reported the identification and retrospective
validation of a circulating 9-miRNA profile for detection of
early stage breast cancer using miRNAs isolated from serum
samples obtained in the late 90’s from 48 women with early
breast cancer and 24 healthy controls. Serum samples from
an additional cohort of 111 women (60 with early stage breast
cancer and 51 controls) were used for validation and
confirmed the ability of the 9-miRNA profile to distinguish be-
tween women with breast cancer and healthy individuals
(Kodahl et al., 2014).
To further develop this assay for clinical use, we evaluated
the blood-based 9-miRNA profile of a prospective cohort of
women undergoing clinical mammography (N ¼ 197). This
cohort was comprised of 18% invasive cancer patients
(N ¼ 36), and 82% clinically healthy controls (N ¼ 161), with
an age-range of 50e74 years. Every second control was chro-
nologically selected to obtain a 2:1 ratio (controls to cases),
resulting in miRNA profiling of 116 women. Our finding sup-
ports the utility of the 9-miRNA profile for early detection of
breast cancer, which would allow initiation of treatment at
an earlier time point.
2. Materials and methods
2.1. Breast cancer patients and healthy controls
Women undergoing clinical mammography due to recall from
screening mammography were asked to participate in the
study, and upon signing the informed consent, blood was
drawn from 197 women (aged 50e74 years) from October
2013 to July 2015. For miRNA profiling, all invasive breast can-
cer cases were included (N ¼ 36), and every second chronolog-
ical database entry of a woman with no mammography-
detected breast cancer was selected for the control group
(N ¼ 80), resulting in a 2:1 ratio of healthy controls vs. breast
cancer cases. Breast cancer diagnosis was confirmed by biopsy
and surgical specimen. Follow-up of healthy controls consist-
ing of review of medical files and/or new mammograms was
performed in April 2016; follow-up period: 0.7e2.4 years. Blood
samples were collected prior to clinical mammography and
serum was isolated according to SOPs of the Danish Cancer
Biobank (DCB Herlev Hospital, 2016). Briefly, serum was pre-
pared within 1 h of blood collection by coagulation between
30 and 120 min, followed by centrifugation at 4 C, 2000 g for
10 min, and immediately stored after fractionation at
80 C. Clinical characteristics of those included in the statis-
tical analysis are listed in Table 1. The study is approved by the
Regional Ethical Committee (ID: S-20100132), and all partici-
pants signed informed consent. The REMARK guidelines
were followed where possible (McShane et al., 2005).
2.2. Isolation of RNA from serum
Total RNA was extracted from serum using the miRCURY
RNA isolation kit (Exiqon, Denmark), including addition of
1 mg carrier-RNA per 60 mL lysis and finally eluted in 50 mL
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RNase-free water. The samples were immediately stored at
80 C until further analysis.
2.3. miRNA real-time PCR
Reverse transcription was conducted with 2 ml RNA in 10 ml re-
actions using the miRCURY LNA Universal RT microRNA
PCR, Polyadenylation and cDNA synthesis kit (Exiqon) in tech-
nical triplicates. cDNA was diluted 50 and assayed in 10 mL
PCR reactions according to the protocol for miRCURY LNA
Universal RT microRNA PCR; each microRNA was assayed
once by qPCR on the microRNA Ready-to-Use PCR, custom
Pick and Mix Panel using ExiLENT SYBR Green master mix
(Exiqon). Negative controls excluding template from the
reverse transcription reaction was performed and profiled in
the same manner as the samples. Amplification was per-
formed in a LightCycler 480 Real-Time PCR System (Roche,
Germany) in 384 well plates, and the amplification curves
were analyzed using the Roche LC software both for determi-
nation of Cq (by the 2nd derivative method) and for melting
curve analysis.
2.4. Sample quality
Raw data and all assays were inspected for distinct melting
curves and the Tm was verified to be within known specifica-
tions for the assay. Only assays detected with 3 Cqs less than
the negative control, and with Cq <37, were included in the
data analysis. DNA spike-ins’ were used to assess the quality
of the RNA extraction, RT and qPCR steps. These assays
were not used for normalization. Whether hemolysis had
occurred in the blood samples was evaluated by determining
the ratio of miRNA-451 (expressed in red blood cells) and
miRNA-23a (stable in blood, and not affected by hemolysis)
(Blondal et al., 2013) and samples exhibiting a ratio of >7
were excluded.
2.5. Normalization and data analysis
In our previous publication, miRNA-10b-5p was identified to
be the most stable miRNA, based on 65 miRNA assays, and
therefore used as reference miRNA. The risk score was calcu-
lated using the normalized (DCp,target ¼ log2 (Cp target
miRNA)log2 (Cp miRNA-10b-5p)) miRNA values, centered
and standardized to a standard deviation of 1, of the 9miRNAs
(miR-15a, miR-18a, miR-107, miR-133a, miR-139-5p, miR-143,
miR-145, miR-365, miR-425) and the following equation:
score ¼ 0.934 þ (0.152* DCp [miR-143-3p]) þ (0.435* DCp
[miR-139-5p]) þ (0.341* DCp [miR-107]) þ (1.124* DCp [miR-
145-5p]) þ (0.702* DCp [miR-15a-5p]) þ (0.31* DCp [miR-425-
5p]) þ (0.18* DCp [miR-18a-5p]) þ (0.275* DCp [miR-133a-3p])
þ (0.134* DCp [miR-365a-3p]). This score can be converted
into a predicted probability of having breast cancer by the
equation ¼ 1/(1 þ exp(score)). Comparison between groups
was performed by means of t-tests; discrimination perfor-
mance was assessed using ROC curves and the corresponding
area under the curve (AUC).
3. Results
3.1. Patient characteristics
A consecutive cohort of women (N ¼ 197) who had undergone
clinical mammography due to recall from screening
mammography was evaluated, 36 of which had invasive
breast cancer. The controls were then selected to obtain a
2:1 ratio of controls to cases, choosing every second woman
included chronologically in the study, leading to a total of
116 samples for miRNA profiling. The clinical characteristics
of these participants are summarized in Table 1. Since our
previous study identified no difference in miRNA expression
according to lymph node involvement, age, menopausal sta-
tus or tumor size between breast cancer samples, these pa-
rameters were not used to further stratify the patients. The
qPCR data generated was analyzed as in our previous study
(Kodahl et al., 2014), including stringent quality control mea-
sures. Two serum samples, both from individuals in whom
no breast cancer was detected by clinical mammography,
were excluded due to the risk of hemolysis to eliminate any
potential influence on our results.
3.2. Clinical utility of the 9-miRNA profile
The 9-miRNA profile was significantly different between pa-
tients with ERþ breast cancer and healthy controls
(p < 0.0001, (95% CI [0.41; 0.86])) with an AUC of 0.58
(Figure 1A) following a completely standardized flow of anal-
ysis, confirming our previously published results. We also
investigated the performance of the profile for the complete
dataset, including the ER breast cancer samples (Figure 1B).
Table 1 e Clinical characteristics of the study patient cohort.
Parameter Patients,
ERþ
Patients,
ER
Controls
Total 31 5 80
Biopsies 31 5 4
Age, years
(median, range)
63 (50e70) 61 (56e63) 54 (50e74)
Surgery
Lumpectomy 24 3
Mastectomy 7 1
Inoperablea 0 1
Diagnosis
IDC 25 4
ILC 2 0
Mixed IDC/ILC 3 0
Tubular 1 0
NAa 0 1
Tumor size mm
(median, range)
12 (4e34) 18 (12e58)
Nodal status
0 22 3
1e3 9 1
Selected LNs biopsieda 1
HER2 status
Normal 30 5
Amplified 1 0
a The inoperable patient.
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This profile also reached significance (p < 0.0001, 95% CI
[0.35; 0.77]), and there was a slight increase in the AUC
(0.61) for early detection of combined ERþ and ER breast
cancer.
The qPCR data for the 9-miRNAs can be transformed into a
risk score that can be convertedmathematically to a predicted
probability of breast cancer (Figure 2). This predicted probabil-
ity functions as a continuous value, and its performance was
evaluated by reviewing whether any of the women in whom
no breast cancer was detected by clinical mammography sub-
sequently developed breast cancer within a follow-up period
of 0.7e2.4 years. One woman was diagnosed with bilateral
breast cancer 348 days after blood sampling, and did not
have a biopsy taken at clinical mammography. Her 9-miRNA
profile score was 0.978, resulting in a predicted probability of
having breast cancer of 0.73 (i.e. 73%).
To assess the sensitivity and specificity of the 9-miRNA
profile, a cut-off of 0.56 (risk score value) was chosen, yielding
0.70 and 0.47, or 0.73 and 0.44, respectively, for the ERþ group
only or the combined ERþ and ER group.
4. Discussion
In this study, we verified our circulating 9-miRNA profile
(Kodahl et al., 2014) in a prospectively collected cohort of
post-menopausal women undergoing clinical mammography
due to recall after screening mammography. A ratio of 2:1 of
clinically healthy controls vs. breast cancer patients, respec-
tively, was chosen to minimize the potential risk of bias, as
some of the healthy controls may have clinically undetectable
cancer or inflammation that could potentially affect the re-
sults. The set-up of this study mimicked a diagnostic test in
a standard clinical setting, following clear SOPs and core facil-
ity techniques.
Although mammography is a widely used and approved
method for detecting breast cancer, it is not optimal since
the test can be affected by breast density, is operator-
dependent and is quite uncomfortable. Twenty seven percent
of the women included in our cohort had a biopsy taken at
time of the clinical mammography (N ¼ 53/197), and 68%
(N ¼ 36) were found to have cancer. The women selected for
biopsy were not only based on X-ray mammography, but
also clinical exams and ultrasound. Screeningmammography
has a high percentage of recall, and most turn out not to have
cancer. In a recent American meta-analysis (2016), a 42% cu-
mulative rate of false-positives over 10 years were found
upon biennial screening (Nelson et al., 2016a,b). Furthermore,
the invasive lobular carcinomas (ILCs) have long been recog-
nized as difficult to image by X-ray due to the growth pattern
of diffuse infiltration of single rows of malignant cells, which
does not destroy the underlying anatomic structures (Johnson
et al., 2015). A normal distribution (Lakhani et al., 2016) of
invasive ductal carcinomas (IDCs) (80%) and ILCs (11%) was
observed in this study.
Cell-free (cf) miRNAs have all the characteristics of an
optimal blood-based cancer biomarker, such as stability in
both the blood stream and during handling and storage, and
likely reflect the tumor in its entirety compared to a single bi-
opsy. Cell-free miRNAs have been determined to be RNase-
resistant in plasma as they were found to be bound with com-
plexes of the protein AGO2, but a minority were also found to
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Figure 1 e ROC curve analysis using the 9-miRNA profile for
discriminating breast cancer cases from controls (N [ 78), i.e.
without a suspicious finding on the mammogram. A) Graph only
including the ERD breast (N [ 31) cancer cases, with an
AUC [ 0.58 (p< 0.0001, (95% CI [0.41; 0.86])). B) Graph of the
ERD and ERL breast cancer samples combined (N[ 36), having an
AUC [ 0.61 (p< 0.0001, (95% CI [0.35; 0.77])).
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Figure 2 e Visualization of the relation of the risk score to the
predicted probability of having breast cancer. The score was
calculated from the normalized qPCR expression data of the 9
miRNAs using the formula provided in Material and Methods.
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be associated with vesicles or exosomes (Mitchell et al., 2008;
Mathivanan et al., 2010).
The published miRNA blood-based profiles for detection of
early breast cancer have minimal overlap in which miRNAs
are included (Ng et al., 2013; Zhu et al., 2009; Cuk et al., 2013;
Heneghan et al., 2010; Zhang et al., 2015; Freres et al., 2016;
Hagrass et al., 2015; Mishra et al., 2015). This lack of consis-
tency could be due to redundancy in miRNA function, and
several miRNAs could be deregulated in the samemanner un-
der certain conditions, replacing one miRNA with another.
Another explanation for the lack of overlap could be the tech-
nical approach, from the pre-analytical techniques of blood
sampling and isolation of serum/plasma, to the use of assays
(qPCR, array or sequencing) and reagents.
All women in this validation studywere above the age of 50
and thus most likely post-menopausal, representing the com-
mon mammography screening population. Our profile was
previously developed, including thorough investigation of
the normalization procedure, and we could significantly iden-
tify invasive breast cancer cases among healthy controls
(Kodahl et al., 2014). This was underscored by one woman
with a 73% predicted probability of breast cancer who had
no evidence of breast cancer at the time of clinical mammog-
raphy and blood sample, but in whom a palpable lump and a
breast cancer diagnosis was confirmed nearly a year later.
Based on our blood test, this individual could potentially
have undergone further medical exams and had treatment
initiated much earlier. As our population was restricted in
available ERebreast cancer samples, we will need to further
investigate this in a larger ER breast cancer population to
confirm the all-round performance of this 9-miRNAprofile. In-
vestigations of non-malignant breast lesions to identify the
potential to discriminate between these and invasive breast
cancer will also be required. Furthermore, it would be very
interesting to examine the profile in younger women, as their
denser breast tissue poses a challenge for mammography.
5. Conclusion
Overall, while screening mammography has generally been
shown to reduce breast cancer mortality, a recent study indi-
cates that the effectmay only be borderline statistically signif-
icant, particularly for younger women (Nelson et al., 2016a,b).
MicroRNAs are very potent blood-based biomarkers, but their
use in the clinical setting is still limited due to lack of repro-
ducibility, limited sample sizes investigated and the lack of in-
dependent validation cohorts. Ideally, a blood-based
biomarker profile combined withmammogram findings could
increase both sensitivity and specificity and render an earlier,
more precise, diagnosis of breast cancer. This potential of the
9-miRNA profile was underscored by the subsequent identifi-
cation of a interval breast cancer in one woman who, in our
initial analysis, had a 73% risk of breast cancer based on our
9-miRNA profile blood test, but no detectable disease at the
time of mammography and blood sampling. As the data ma-
tures, we will investigate whether more interval cancers are
diagnosed, and further assess the miRNA profile to see
whether the 9-miRNA profile could have indicated the pres-
ence of a mammographically-undetectable cancer.
Authors’ contribution
MBL, ARK and HJD participated in the study design. MBL coor-
dinated the project, performed data interpretation and wrote
the first draft of the manuscript. HB performed the statistical
analysis. ARK, HB and HJD assisted in writing the manuscript,
and all authors have read and approved the final manuscript.
Funding
The public and private foundations that supported the study
had no role in the design and conduct of this study; in the
collection, management, analysis and interpretations of the
data; or in the preparation, review or approval of the manu-
script. The authors had full access to all the data in the study
and had the final responsibility for the decision to submit the
manuscript for publication.
This work was supported by the Danish Cancer Society
[grant number: A6362, H.J. Ditzel], A Race Against Breast Can-
cer (H.J. Ditzel), Odense University Hospital Research Council
(H.J. Ditzel), Dean’s Fund for Project Development at Univer-
sity of Southern Denmark (H.J. Ditzel), AgeCare OUH EliteCen-
ter (H.J. Ditzel), and Danish Center for Translational Breast
Cancer Research (H.J. Ditzel).
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
The Danish CancerBiobank (DCB) is acknowledged for biolog-
ical material and for the data regarding handling and storage.
We would like to thank the Mammography Screening
personnel, particularly Bente Magelund, and the Department
of Clinical Biochemistry and Pharmacology, Odense Univer-
sity Hospital, for excellent assistance with the recruitment
of women and blood drawing, and M. Kat Occhipinti for edito-
rial assistance.
R E F E R E N C E S
Berg, W.A., 2016. Nuclear breast imaging: clinical results and
future directions. J. Nucl. Med. 57 (Suppl. 1), 46Se52S.
Blondal, T., Jensby, N.S., Baker, A., Andreasen, D., Mouritzen, P.,
Wrang, T.M., Dahlsveen, I.K., 2013. Assessing sample and
miRNA profile quality in serum and plasma or other biofluids.
Methods 59, S1eS6.
Botezatu, I., Serdyuk, O., Potapova, G., Shelepov, V., Alechina, R.,
Molyaka, Y., Ananev, V., Bazin, I., Garin, A., Narimanov, M.,
Knysh, V., Melkonyan, H., Umansky, S., Lichtenstein, A., 2000.
Genetic analysis of DNA excreted in urine: a new approach for
detecting specific genomic DNA sequences from cells dying in
an organism. Clin. Chem. 46, 1078e1084.
Chestnov, O., Sepulveda, C., Murad, H., Heneghan, C.,
Gartlehner, G., Bramley, D., Norris, S., 2014. WHO Position
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 6 2 1e1 6 2 6 1625
Paper on Mammography Screening. http://apps.who.int/iris/
bitstream/10665/137339/1/9789241507936_eng.pdf?
ua¼1&ua¼1.
Chim, S.S., Shing, T.K., Hung, E.C., Leung, T.Y., Lau, T.K.,
Chiu, R.W., Lo, Y.M., 2008. Detection and characterization of
placental microRNAs in maternal plasma. Clin. Chem. 54,
482e490.
Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S.,
Turchinovich, A., Arlt, D., Rath, M., Sohn, C., Benner, A.,
Junkermann, H., Schneeweiss, A., Burwinkel, B., 2013.
Circulating microRNAs in plasma as early detection markers
for breast cancer. Int. J. Cancer 132, 1602e1612.
DCB Herlev Hospital, 2016. The Danish Cancer Biobank. http://
www.danskcancerbiobank.dk/.
Freres, P., Wenric, S., Boukerroucha, M., Fasquelle, C., Thiry, J.,
Bovy, N., Struman, I., Geurts, P., Collignon, J., Schroeder, H.,
Kridelka, F., Lifrange, E., Jossa, V., Bours, V., Josse, C.,
Jerusalem, G., 2016. Circulating microRNA-based screening
tool for breast cancer. Oncotarget 7, 5416e5428.
Gilbert, F.J., Tucker, L., Young, K.C., 2016. Digital breast
tomosynthesis (DBT): a review of the evidence for use as a
screening tool. Clin. Radiol. 71, 141e150.
Hagrass, H.A., Sharaf, S., Pasha, H.F., Tantawy, E.A.,
Mohamed, R.H., Kassem, R., 2015. Circulating microRNAs e a
new horizon in molecular diagnosis of breast cancer. Genes
Cancer 6, 281e287.
Heneghan, H.M., Miller, N., Lowery, A.J., Sweeney, K.J., Newell, J.,
Kerin, M.J., 2010. Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann. Surg. 251,
499e505.
Johnson, K., Sarma, D., Hwang, E.S., 2015. Lobular breast cancer
series: imaging. Breast Cancer Res. 17, 94.
Kodahl, A.R., Lyng, M.B., Binder, H., Cold, S., Gravgaard, K.,
Knoop, A.S., Ditzel, H.J., 2014. Novel circulating microRNA
signature as a potential non-invasive multi-marker test in ER-
positive early-stage breast cancer: a case control study. Mol.
Oncol. 8, 874e883.
Kosaka, N., Iguchi, H., Ochiya, T., 2010. Circulating microRNA in
body fluid: a new potential biomarker for cancer diagnosis and
prognosis. Cancer Sci. 101, 2087e2092.
Lakhani, S.R., Ellis, I.O., Schnitt, S.J., Tan, P.H., van de Vijver, M.J.,
2016. WHO Classification of Tumours of the Breast. IARC Press.
Lawrie, C.H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P.,
Pulford, K., Banham, A.H., Pezzella, F., Boultwood, J.,
Wainscoat, J.S., Hatton, C.S., Harris, A.L., 2008. Detection of
elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma. Br. J. Haematol.
141, 672e675.
Mathivanan, S., Ji, H., Simpson, R.J., 2010. Exosomes: extracellular
organelles important in intercellular communication.
J. Proteomics 73, 1907e1920.
McShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M.,
Clark, G.M., 2005. Reporting recommendations for tumor
marker prognostic studies (REMARK). J. Natl. Cancer Inst. 97,
1180e1184.
Minchin, R.F., Carpenter, D., Orr, R.J., 2001. Polyinosinic acid and
polycationic liposomes attenuate the hepatic clearance of
circulating plasmid DNA. J. Pharmacol. Exp. Ther. 296,
1006e1012.
Mishra, S., Srivastava, A.K., Suman, S., Kumar, V., Shukla, Y.,
2015. Circulating miRNAs revealed as surrogate molecular
signatures for the early detection of breast cancer. Cancer Lett.
369, 67e75.
Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K.,
Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J.,
O’Briant, K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W.,
Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L.,
Nelson, P.S., Martin, D.B., Tewari, M., 2008. Circulating
microRNAs as stable blood-based markers for cancer
detection. Proc. Natl. Acad. Sci. U.S.A 105, 10513e10518.
Mittmann, N.M., Stout, N.K., Lee, P., Tosteson, A.N., Trentham-
Dietz, A., Alagoz, O., Yaffe, M.J., 2015. Total cost-effectiveness
of mammography screening strategies. Health Rep. 26, 16e25.
Nelson, H.D., Fu, R., Cantor, A., Pappas, M., Daeges, M.,
Humphrey, L., 2016a. Effectiveness of breast cancer screening:
systematic review and meta-analysis to update the 2009 U.S.
Preventive Services Task Force Recommendation. Ann. Intern.
Med. 164, 244e255.
Nelson, H.D., Pappas, M., Cantor, A., Griffin, J., Daeges, M.,
Humphrey, L., 2016b. Harms of breast cancer screening:
systematic review to update the 2009 U.S. Preventive
Services Task Force Recommendation. Ann. Intern. Med 164,
256e267.
Ng, E.K., Li, R., Shin, V.Y., Jin, H.C., Leung, C.P., Ma, E.S., Pang, R.,
Chua, D., Chu, K.M., Law, W.L., Law, S.Y., Poon, R.T.,
Kwong, A., 2013. Circulating microRNAs as specific biomarkers
for breast cancer detection. PLoS One 8, e53141.
Schwarzenbach, H., Nishida, N., Calin, G.A., Pantel, K., 2014.
Clinical relevance of circulating cell-free microRNAs in cancer.
Nat. Rev. Clin. Oncol. 11, 145e156.
Witwer, K.W., 2015. Circulating microRNA biomarker studies:
pitfalls and potential solutions. Clin. Chem. 61, 56e63.
Zhang, L., Xu, Y., Jin, X., Wang, Z., Wu, Y., Zhao, D., Chen, G.,
Li, D., Wang, X., Cao, H., Xie, Y., Liang, Z., 2015. A circulating
miRNA signature as a diagnostic biomarker for non-invasive
early detection of breast cancer. Breast Cancer Res. Treat. 154,
423e434.
Zhu, W., Qin, W., Atasoy, U., Sauter, E.R., 2009. Circulating
microRNAs in breast cancer and healthy subjects. BMC. Res.
Notes 2, 89.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 6 2 1e1 6 2 61626
